Fate Therapeutics, Inc. (NASDAQ:FATE)’s Basic Consolidated EPS Came In At $-1.1769

0

The annual basic consolidated EPS for Fate Therapeutics, Inc. (NASDAQ:FATE) posted annual basic consolidated EPS of $-1.1769 for the year period ended2015-12-31. But basic consolidated EPS for the quarter period ended 2015-12-31 came in at $-1.1769.

What About EPS from continuing operations

Fate Therapeutics, Inc. (NASDAQ:FATE)’s EPS from continuing operations for the annual period ended 2015-12-31 came in at -1.1769. On quarterly basis, EPS from continuing operations stood at $-1.1769 for the three-month period ended 2015-12-31.

EPS contribution from parent

Fate Therapeutics, Inc. (NASDAQ:FATE) received of $-1.1769 EPS boost from the parent company for the annual period ended 2015-12-31. For the quarter period ended 2015-12-31, the company received EPS boost of $-1.1769 from its parent company.

What About Basic net EPS

The company’s basic net EPS for the annual period ended 2015-12-31 was$-1.18, but for the quarter period ended 2015-12-31 the basic net EPS was $-1.18.

What About Consolidated Diluted EPS?

Fate Therapeutics, Inc. (NASDAQ:FATE) posted consolidated diluted EPS of $-1.1769 for the annual period ended 2015-12-31. On the other hand, consolidated diluted EPS for the quarterly period ended 2015-12-31 stood at $-1.1769.

Basic diluted EPS

The company’s diluted EPS from continuing operation stood at $-1.1769 for the annual period ended 2015-12-31. On quarter basis, diluted EPS from continuing operations was $-1.1769 for the three-month period ended 2015-12-31.

Net diluted EPS

Fate Therapeutics, Inc. (NASDAQ:FATE) posted net diluted EPS of $-1.18for the annual period ended 2015-12-31. On the other hand, it posted net diluted EPS of $-1.18 for thequarterly period ended 2015-12-31.

What portion of diluted EPS came from parent?

For the annual period ended 2015-12-31, the parent company of Fate Therapeutics, Inc. (NASDAQ:FATE) contributed diluted EPS of $-1.1769. The diluted EPS contribution from the parent for the quarter ended 2015-12-31 stood at $-1.1769.

The company’s net basic EPS for the annual period ended 2015-12-31 was $-1.18 while for the quarter period ended 2015-12-31 it was $-1.18.

Fate Therapeutics, Inc. (NASDAQ:FATE) had average basic shares outstanding of 25.484 for the annual period ended 2015-12-31 and 25.484 for the quarter period ended 2015-12-31.The number of diluted shares outstanding was 25.484 for the annual period ended 2015-12-31 and 25.484 for the quarter ended 2015-12-31.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 28 times, 1 visits today)